Provided by Tiger Trade Technology Pte. Ltd.

DaVita HealthCare Partners

180.68
+1.801.01%
Pre-market: 180.680.00000.00%07:00 EDT
Volume:461.80K
Turnover:83.60M
Market Cap:11.60B
PE:14.90
High:182.53
Open:180.00
Low:178.80
Close:178.88
52wk High:247.49
52wk Low:101.00
Shares:64.20M
Float Shares:32.63M
Volume Ratio:0.69
T/O Rate:1.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):12.13
EPS(LYR):9.84
ROE:88.48%
ROA:7.52%
PB:-15.16
PE(LYR):18.36

Loading ...

DaVita Inc. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains

Dow Jones
·
Apr 23

Veterans still battling with DVA claims system

prnewswire
·
Apr 22

DaVita schedules first-quarter results conference call

Reuters
·
Apr 21

DaVita Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Apr 17

Is It Time To Revisit DaVita (DVA) After Mixed Share Price Performance?

Simply Wall St.
·
Apr 12

DaVita Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Apr 10

California law limiting dialysis providers' profits voided by US appeals court

Reuters
·
Apr 08

DaVita Inc. Stock Advances 3.1%, Outperforms Peers

Dow Jones
·
Apr 07

Is DaVita’s (DVA) AI-Driven Home Dialysis Push Redefining Its Long-Term Competitive Moat?

Simply Wall St.
·
Apr 04

DaVita Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Mar 26

AllianceBernstein Global High Income Fund Inc. Publishes Report; NAV $11.42

Reuters
·
Mar 24

DaVita reports 9% Total Quality Score improvement and more than USD 200 million in CKCC shared savings

Reuters
·
Mar 19

DaVita Mixes Strong Value Signals With Distress Score And Insider Selling

Simply Wall St.
·
Mar 18

Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306

prnewswire
·
Mar 17

BRIEF-R1 Therapeutics Announces Launch With An Oversubscribed $77.5 Million Series A Financing

Reuters
·
Mar 17

R1 Therapeutics: Proceeds From Series a Financing to Fund R1's Global Development Program of AP306

THOMSON REUTERS
·
Mar 17

R1 Therapeutics: Financing Was Co-Led by Abingworth, F-Prime, & DaVita Venture Group, With Participation From Curie.bio, Symbiosis, & U.S. Renal Care

THOMSON REUTERS
·
Mar 17

R1 Therapeutics launches with $78 million funding round, secures kidney disorder treatment license

Reuters
·
Mar 17

DaVita Inc. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
Mar 13

DaVita Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Mar 05